Valuation: Monopar Therapeutics Inc.

Market Cap 655M 573M 526M 491M 930M 62.37B 945M 6.32B 2.46B 30.66B 2.46B 2.41B 106B P/E 2026 *
-42.4x
P/E 2027 * -28.2x
Enterprise Value 537M 469M 431M 402M 762M 51.08B 774M 5.17B 2.01B 25.11B 2.01B 1.97B 86.53B EV / Sales 2026 *
-
EV / Sales 2027 * 34.2x
Free-Float
76.77%
Yield 2026 *
-
Yield 2027 * -
1 day+2.90%
1 week+11.53%
Current month+5.62%
1 month+61.48%
3 months+77.38%
6 months+48.14%
Current year+49.75%
1 week 86.3
Extreme 86.3
100.32
1 month 57.7
Extreme 57.7
100.32
Current year 50.07
Extreme 50.07
100.32
1 year 29.18
Extreme 29.18
105
3 years 1.37
Extreme 1.3695
105
5 years 1.37
Extreme 1.3695
105
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 2014-11-30
Director of Finance/CFO 54 2025-03-02
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 2014-11-30
Chairman 73 2014-11-30
Director/Board Member 84 2017-03-31
Date Insider Type Main position Quantity % Market Cap.
06-25Free

Director

1,284 0.0192%
03-30Fiscal year

Founder

15,436 0.2310%
03-30Fiscal year

Chief Operating Officer

8,599 0.1287%
Change 5-day change 1-year change 3-year change Capi.($)
+2.90%+11.53%+169.77%+2,276.43% 655M
+1.70%+7.41%+3.12%+8.46% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +2.25%+6.40%+89.90%+359.87% 24.63B
Weighted average by Cap. +2.07%+6.55%+90.97%+143.85%

Financials

2026 *2027 *
Net sales - 15.85M 13.86M 12.73M 11.87M 22.51M 1.51B 22.85M 153M 59.43M 742M 59.49M 58.21M 2.56B
Net income -20.16M -17.62M -16.2M -15.1M -28.64M -1.92B -29.07M -194M -75.59M -944M -75.68M -74.05M -3.25B -35.78M -31.28M -28.74M -26.79M -50.82M -3.41B -51.59M -345M -134M -1.67B -134M -131M -5.77B
Net Debt -119M -104M -95.25M -88.79M -168M -11.29B -171M -1.14B -445M -5.55B -445M -435M -19.12B -112M -98.21M -90.25M -84.12M -160M -10.7B -162M -1.08B -421M -5.26B -422M -413M -18.12B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
22
Date Price Change Volume
26-07-02 US$97.79 +2.90% 188,267
26-07-01 US$95.03 +2.64% 177,531
26-06-30 US$92.59 -2.08% 111,800
26-06-29 US$94.56 +7.85% 119,921
26-06-26 US$87.68 +0.06% 310,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
97.79USD
Average target price
113.62USD
Spread / Average Target
+16.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock